Human epidermal growth factor 2 (Her2) is overexpressed in approximately 30% of breast cancers and administration of Herceptin® (trastuzumab, a monoclonal antibody against Her2) has shown efficacy in Her2 positive breast cancer patients [22]. The gene discussed is ERBB2; the disease is breast carcinoma.